CYTOKINE COMBINATIONS IN IMMUNOTHERAPY FOR SOLID TUMORS - A REVIEW

被引:32
作者
HEATON, KM
GRIMM, EA
机构
[1] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,BOX 79,1515 HOLCOMBE,HOUSTON,TX 77030
[2] UNIV TEXAS,MD ANDERSON CANC CTR,DEPT GEN SURG,HOUSTON,TX 77030
关键词
CYTOKINES; IMMUNOTHERAPY; IL-2; IFN; TNF;
D O I
10.1007/BF01518513
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The use of cytokines alone or in combination with other cytokines or cytotoxic drugs has had a profound effect upon widely metastatic disease in many cases. However, despite the encouraging results in early trials, there is much room for improvement. Few responses to these combinations are complete, and toxicity has in some cases been quite severe. Changes in dose, route, or schedule of administration of the drugs, or the development of cytokine analogs may lead to more efficacious and less toxic regimens. In addition, new cytokines such as interleukin(IL)-7 and IL-12 are currently under investigation for potential use in future immunotherapy trials. These prospects and the use of cytokine combinations are promising advances in the treatment of human cancer.
引用
收藏
页码:213 / 219
页数:7
相关论文
共 81 条
[1]  
ABBRUZZESE JL, 1989, CANCER RES, V49, P4057
[2]   CORRELATION OF EOSINOPHILIA WITH CLINICAL-RESPONSE IN PATIENTS WITH ADVANCED-CARCINOMA TREATED WITH LOW-DOSE RECOMBINANT INTERLEUKIN-2 AND MITOMYCIN-C [J].
ARINAGA, S ;
KARIMINE, N ;
TAKAMUKU, K ;
NANBARA, S ;
INOUE, H ;
ABE, R ;
WATANABE, D ;
MATSUOKA, H ;
UEO, H ;
AKIYOSHI, T .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1992, 35 (04) :246-250
[3]  
BUDD GT, 1989, CANCER RES, V49, P6432
[4]   PHASE-I TRIAL OF CONTINUOUS INFUSION INTERLEUKIN-2 AND DOXORUBICIN IN PATIENTS WITH REFRACTORY MALIGNANCIES [J].
BUKOWSKI, RM ;
SERGI, JS ;
BUDD, GT ;
MURTHY, S ;
TUBBS, R ;
GIBSON, V ;
BAUER, L ;
STANLEY, J ;
GAUTAM, S ;
FINKE, J .
JOURNAL OF IMMUNOTHERAPY, 1991, 10 (06) :432-439
[5]   ENDOTOXIN-INDUCED SERUM FACTOR THAT CAUSES NECROSIS OF TUMORS [J].
CARSWELL, EA ;
OLD, LJ ;
KASSEL, RL ;
GREEN, S ;
FIORE, N ;
WILLIAMSON, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1975, 72 (09) :3666-3670
[6]  
CREAGAN ET, 1988, CANCER, V62, P2472, DOI 10.1002/1097-0142(19881215)62:12<2472::AID-CNCR2820621203>3.0.CO
[7]  
2-G
[8]   INTERLEUKIN-2 AND HIGH-DOSE CISPLATIN IN PATIENTS WITH METASTATIC MELANOMA - A PILOT-STUDY [J].
DEMCHAK, PA ;
MIER, JW ;
ROBERT, NJ ;
OBRIEN, K ;
GOULD, JA ;
ATKINS, MB .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (10) :1821-1830
[9]   A PHASE-I TRIAL OF RECOMBINANT HUMAN-TUMOR NECROSIS FACTOR AND INTERFERON-GAMMA - EFFECTS OF COMBINATION CYTOKINE ADMINISTRATION INVIVO [J].
DEMETRI, GD ;
SPRIGGS, DR ;
SHERMAN, ML ;
ARTHUR, KA ;
IMAMURA, K ;
KUFE, DW .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (10) :1545-1553
[10]  
DEMULDER PH, 1991, P AM SOC CLIN ONCOL, V10, P166